nach oben

Erschienen in:

19.09.2021 | Original Article

Serum BDNF and cognitive dysfunction in SLE: findings from a cohort of 111 patients

verfasst von: Helena Alessi, Lívia Almeida Dutra, Lília A. Maria, Paula C. Coube, Karina Hoshino, Fabiano F. de Abrantes, Fernanda C. Lopes, Alexandre Wagner S. de Souza, Cristiane Kayser, Orlando G. P. Barsottini

Erschienen in: Clinical Rheumatology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Objective

The association between brain-derived neurotrophic factor (BDNF) and neuropsychiatric systemic lupus erythematosus (NPSLE) is controversial in the literature. Cognitive dysfunction (CD) is a common, underdiagnosed NPSLE manifestation, but its pathophysiology is unknown. Thus, we investigate serum BDNF as a potential biomarker of CD in a cohort of SLE patients.

Methods

We included 63 SLE patients, 48 NPSLE, and 57 age- and gender-matched controls (CON). All participants underwent neuropsychological assessment. Data on cardiovascular comorbidities, SLE disease activity index (SLEDAI), and Systemic Lupus International Collaborating Clinics damage index (SLICC-DI) were compiled. Multiple regression analyses evaluated predictors of serum BDNF levels.

Results

Serum BDNF levels were lower in SLE and NPSLE patients than in CON (SLE 800.4 ± 502.7 vs. NPSLE 779.7 ± 426.3 vs. CON 1,345.5 ng/mL ± 438.4; p < 0.001). In addition, hypertension (B: − 192.5, SE: 84.3, 95% CI: − 359.7 to − 25.3, p = 0.024) and SLICC-DI score (B: − 75.9, SE: 27.2, 95% CI: − 129.8 to − 22, p = 0.006) were predictors of serum BDNF levels in SLE. There was no relation between BDNF levels and CD.

Conclusion

BDNF levels are lower in SLE patients than CON and inversely associated with hypertension and SLICC-DI scores. No association between BDNF levels and CD or NPSLE was observed in this cohort. These findings indicate that BDNF may be associated with overall burden in SLE rather than specific manifestations such as cognition impairment.

Key Points

• BDNF is associated with an overall burden in SLE rather than specific manifestations such as cognition dysfunction.

• BDNF levels are reduced in patients with SLE, and higher SLICC-DI scores and hypertension are independent predictors of lower serum BDNF levels.

• The cognitive dysfunction rate is elevated (46%) among Brazilian SLE patients.

Hanly JG, Kozora E, Beyea SD, Birnbaum J (2019) Nervous system disease in systemic lupus erythematosus: current status and future directions. Arthritis Rheumatol 71:33–42. https://doi.org/10.1002/art.40591CrossRefPubMed

Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL et al (2002) Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 58:1214–1220CrossRef

Govoni M, Bortoluzzi A, Padovan M, Silvagni E, Borrelli M, Donelli F et al (2016) The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J Autoimmun 74:41–72. https://doi.org/10.1016/j.jaut.2016.06.013CrossRefPubMed

Mikdashi JA (2007) Proposed response criteria for neurocognitive impairment in systemic lupus erythematosus clinical trials. Lupus 16:418–425. https://doi.org/10.1177/0961203307079044CrossRefPubMed

McLaurin EY, Holliday SL, Williams P, Brey RL (2005) Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 64:297–303. https://doi.org/10.1212/01.WNL.0000149640.78684.EACrossRefPubMed

Murray SG, Yazdany J, Kaiser R, Criswell LA, Trupin L, Yelin EH et al (2012) Cardiovascular disease and cognitive dysfunction in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 64:1328–1333. https://doi.org/10.1002/acr.21691CrossRef

Tomietto P, Annese V, D’Agostini S, Venturini P, La Torre G, De Vita S et al (2007) General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus. Arthritis Rheum 57:1461–1472. https://doi.org/10.1002/art.23098CrossRefPubMed

Lapteva L, Nowak M, Yarboro CH, Takada K, Roebuck-Spencer T, Weickert T et al (2006) Anti–N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 54:2505–2514. https://doi.org/10.1002/art.22031CrossRefPubMed

Lessmann V, Gottmann K, Malcangio M (2003) Neurotrophin secretion: current facts and future prospects. Prog Neurobiol 69:341–374. https://doi.org/10.1016/S0301-0082(03)00019-4CrossRefPubMed

10.

Park H, Poo M (2013) Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci 14:7–23. https://doi.org/10.1038/nrn3379CrossRefPubMed

11.

Tapia-Arancibia L, Aliaga E, Silhol M, Arancibia S (2008) New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res Rev 59:201–220. https://doi.org/10.1016/j.brainresrev.2008.07.007CrossRefPubMed

12.

Buchman AS, Yu L, Boyle PA, Schneider JA, De Jager PL, Bennett DA (2016) Higher brain BDNF gene expression is associated with slower cognitive decline in older adults. Neurology 86:735–741. https://doi.org/10.1212/WNL.0000000000002387CrossRefPubMedPubMedCentral

13.

Fernandes J, Arida RM, Gomez-Pinilla F (2017) Physical exercise as an epigenetic modulator of brain plasticity and cognition. Neurosci Biobehav Rev 80:443–456. https://doi.org/10.1016/j.neubiorev.2017.06.012CrossRefPubMedPubMedCentral

14.

Kalinowska-Łyszczarz A, Pawlak MA, Wyciszkiewicz A, Pawlak-Buś K, Leszczyński P, Puszczewicz M et al (2017) Immune cell neurotrophin production is associated with subcortical brain atrophy in neuropsychiatric systemic lupus erythematosus patients. NeuroImmunoModulation 24:320–330. https://doi.org/10.1159/000487139CrossRefPubMed

15.

Molendijk ML, Spinhoven P, Polak M, Bus BAA, Penninx BWJH, Elzinga BM (2014) Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol Psychiatry 19:791–800. https://doi.org/10.1038/mp.2013.105CrossRefPubMed

16.

Smith MA, Makino S, Kvetnansky R, Post RM (1995) Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 messenger-RNAs in the hippocampus. J Neurosci 15(3):1768–1777. https://doi.org/10.1523/JNEUROSCI.15-03-01768.1995CrossRefPubMedPubMedCentral

17.

Lise M-C, Sparsa A, Marie I, Lalloué F, Ly K, Martel C et al (2010) Serum neurotrophin profile in systemic sclerosis. PLoS ONE 5:e13918. https://doi.org/10.1371/journal.pone.0013918CrossRefPubMedPubMedCentral

18.

Padern G, Duflos C, Ferreira R, Assou S, Guilpain P, Maria ATJ et al (2021) Identification of a novel serum proteomic signature for primary Sjögren’s syndrome. Front Immunol 12:631539. https://doi.org/10.3389/fimmu.2021.631539CrossRefPubMedPubMedCentral

19.

Li YJ, Yang CS, Lei L, Wu KF, Yang PT, Xiao WG (2014) Serum nerve grow factor and brain-derived neurotrophic factor profiles in Sjögren’s syndrome concomitant with interstitial lung disease. Clin Rheumatol 33:1161–1164. https://doi.org/10.1007/s10067-014-2588-0CrossRefPubMed

20.

Petersen LE, Baptista TSA, Molina JK, Motta JG, do Prado A, Piovesan DM, et al (2018) Cognitive impairment in rheumatoid arthritis: role of lymphocyte subsets, cytokines and neurotrophic factors. Clin Rheumatol 37:1171–1181. https://doi.org/10.1007/s10067-018-3990-9CrossRefPubMed

21.

Tian B, Yang C, Wang J, Hou X, Zhao S, Li Y et al (2019) Peripheral blood brain-derived neurotrophic factor level and tyrosine kinase B expression on T lymphocytes in systemic lupus erythematosus: implications for systemic involvement. Cytokine 123:154764. https://doi.org/10.1016/j.cyto.2019.154764CrossRefPubMed

22.

Rihl M, Kruithof E, Barthel C, De Keyser F, Veys EM, Zeidler H et al (2005) Involvement of neurotrophins and their receptors in spondyloarthritis synovitis: relation to inflammation and response to treatment. Ann Rheum Dis 64:1542–1549. https://doi.org/10.1136/ard.2004.032599CrossRefPubMedPubMedCentral

23.

Grimsholm O, Rantapää-Dahlqvist S, Dalén T, Forsgren S (2008) BDNF in RA: downregulated in plasma following anti-TNF treatment but no correlation with inflammatory parameters. Clin Rheumatol 27:1289–1297. https://doi.org/10.1007/s10067-008-0910-4CrossRefPubMed

24.

Tamashiro LF, Oliveira RD, Oliveira R, Frota ER, Donadi EA, Del-Ben CM et al (2014) Participation of the neutrophin brain-derived neurotrophic factor in neuropsychiatric systemic lupus erythematosus. Rheumatol (Oxford) 53:2182–2190. https://doi.org/10.1093/rheumatology/keu251CrossRef

25.

Noris-García E, Arce S, Nardin P, Lanigan M, Acuña V, Gutierrez F et al (2018) Peripheral levels of brain-derived neurotrophic factor and S100B in neuropsychiatric systemic lupus erythematous. Lupus 27:2041–2049. https://doi.org/10.1177/0961203318804899CrossRefPubMed

26.

Ikenouchi-Sugita A, Yoshimura R, Okamoto T, Umene-Nakano W, Ueda N, Hori H et al (2010) Serum brain-derived neurotrophic factor levels as a novel biological marker for the activities of psychiatric symptoms in systemic lupus erythematosus. World J Biol Psychiatry 11:121–128CrossRef

27.

Petri M, Orbai A-M, Alarcón GS, Gordon C, Merrill JT, Fortin PR et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686. https://doi.org/10.1002/art.34473CrossRefPubMedPubMedCentral

28.

Ainiala H, Hietaharju A, Loukkola J, Peltola J, Korpela M, Metsänoja R et al (2001) Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum 45:419–423. https://doi.org/10.1002/1529-0131(200110)45:5%3c419::aid-art360%3e3.0.co;2-xCrossRefPubMed

29.

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes (1999) Arthritis Rheum 42:599–608. https://doi.org/10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F

30.

Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306. https://doi.org/10.1111/j.1538-7836.2006.01753.xCrossRefPubMed

31.

Gladman DD, Ibañez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288–291PubMed

32.

Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M et al (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369. https://doi.org/10.1002/art.1780390303CrossRefPubMed

33.

Cunha J (2011) Manual da versãoem português das Escalas Beck 1st ed. São Paulo: Casa do Psicólogo

34.

Ikenouchi-Sugita A, Yoshimura R, Ueda N, Kodama Y, Umene-Nakano W, Nakamura J (2008) Continuous decrease in serum brain-derived neurotrophic factor (BDNF) levels in a neuropsychiatric syndrome of systemic lupus erythematosus patient with organic brain changes. Neuropsychiatr Dis Treat 4:1277–1281. https://doi.org/10.2147/ndt.s4259CrossRefPubMedPubMedCentral

35.

Moore E, Huang MW, Putterman C (2020) Advances in the diagnosis, pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus. Curr Opin Rheumatol 32:152–158. https://doi.org/10.1097/BOR.0000000000000682CrossRefPubMedPubMedCentral

36.

Zheng Q, Xu MJ, Cheng J, Chen JM, Zheng L, Li ZG (2017) Serum levels of brain-derived neurotrophic factor are associated with depressive symptoms in patients with systemic lupus erythematosus. Psychoneuroendocrinology 78:246–252. https://doi.org/10.1016/j.psyneuen.2016.12.001CrossRefPubMed

37.

Liang F-Q, Walline R, Earnest DJ (1998) Circadian rhythm of brain-derived neurotrophic factor in the rat suprachiasmatic nucleus. Neurosci Lett 242:89–92. https://doi.org/10.1016/s0304-3940(98)00062-7CrossRefPubMed

38.

Weinstein G, Beiser AS, Choi SH, Preis SR, Chen TC, Vorgas D et al (2014) Serum brain-derived neurotrophic factor and the risk for dementia: the Framingham Heart Study. JAMA Neurol 71:55–61. https://doi.org/10.1001/jamaneurol.2013.4781CrossRefPubMedPubMedCentral

39.

Prokopova B, Hlavacova N, Vlcek M, Penesova A, Grunnerova L, Garafova A et al (2017) Early cognitive impairment along with decreased stress-induced BDNF in male and female patients with newly diagnosed multiple sclerosis. J Neuroimmunol 302:34–40. https://doi.org/10.1016/j.jneuroim.2016.11.007CrossRefPubMed

40.

Costa A, Peppe A, Carlesimo GA, Zabberoni S, Scalici F, Caltagirone C et al (2015) Brain-derived neurotrophic factor serum levels correlate with cognitive performance in Parkinson’s disease patients with mild cognitive impairment. Front Behav Neurosci 9:253. https://doi.org/10.3389/fnbeh.2015.00253CrossRefPubMedPubMedCentral

41.

Hanly JG, Urowitz MB, Su L, Bae S-C, Gordon C, Clarke A et al (2011) Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis 70:1726–1732. https://doi.org/10.1136/ard.2010.148502CrossRefPubMed

42.

Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A (2001) The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 57:496–500. https://doi.org/10.1212/wnl.57.3.496CrossRefPubMed

43.

Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D et al (2017) Dementia prevention, intervention, and care. Lancet 390:2673–2734. https://doi.org/10.1016/S0140-6736(17)31363-6CrossRefPubMed

44.

Sutton EJ, Davidson JE, Bruce IN (2013) The Systemic Lupus International Collaborating Clinics (SLICC) damage index: a systematic literature review. Semin Arthritis Rheum 43:352–361. https://doi.org/10.1016/j.semarthrit.2013.05.003CrossRefPubMed

45.

Wan Ghazali WS, Mohd Daud SM, Mohammad N, Wong KK (2018) SLICC damage index score in systemic lupus erythematosus patients and its associated factors. Med (United States) 97:e12787. https://doi.org/10.1097/MD.0000000000012787CrossRef

46.

Liu Y, Kaplan MJ (2018) Cardiovascular disease in systemic lupus erythematosus: an update. Curr Opin Rheumatol 30:441–448. https://doi.org/10.1097/BOR.0000000000000528CrossRefPubMed

47.

Kaess BM, Preis SR, Lieb W, Beiser AS, Yang Q, Chen TC et al (2015) Circulating brain-derived neurotrophic factor concentrations and the risk of cardiovascular disease in the community. J Am Heart Assoc 4:e001544. https://doi.org/10.1161/JAHA.114.001544CrossRefPubMedPubMedCentral

Titel: Serum BDNF and cognitive dysfunction in SLE: findings from a cohort of 111 patients
verfasst von: Helena Alessi
Lívia Almeida Dutra
Lília A. Maria
Paula C. Coube
Karina Hoshino
Fabiano F. de Abrantes
Fernanda C. Lopes
Alexandre Wagner S. de Souza
Cristiane Kayser
Orlando G. P. Barsottini
Publikationsdatum: 19.09.2021
Verlag: Springer International Publishing
Erschienen in: Clinical Rheumatology / Ausgabe 2/2022
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-021-05915-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

Three-dimensional ultrasonographic imaging of Mikulicz’s disease

Exposure-lag-response associations between extreme environmental conditions and primary Sjögren’s syndrome

Association of quantitative computed tomography ındices with lung function and extent of pulmonary fibrosis in patients with systemic sclerosis

Hypertrophic pachymeningitis in polyarteritis nodosa: a case-based review

Prevalence and factors related to sleep apnoea in ankylosing spondylitis